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Rodrigo Bressan h, Neus Barrantes-Vidal i, Stephan Ruhrmann j, Gabriele Sachs k, 
Lieuwe de Haan a,b, Jentien M. Vermeulen a, EU-GEI High Risk Study1 
a Amsterdam UMC (location AMC), Department of Psychiatry, Amsterdam, the Netherlands 
b Arkin, Institute for Mental Health, Amsterdam, the Netherlands 
c Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom 
d Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom 
e Psychosis Research Institute, Parnassia Group, The Hague, the Netherlands 
f Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road (Locked Bag 10), Parkville, Victoria 485 3052, Australia. 
g Faculty of Medicine, University of Basel, Switzerland 
h LiNC—Lab Interdisciplinar Neurociências Clínicas, Depto Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo—UNIFESP, São Paulo, Brazil 
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A B S T R A C T   
Background: The high prevalence rates and impact of tobacco smoking in individuals with a psychotic disorder 
have become an increasing interest. Little is known about tobacco smoking in individuals at ultra-high risk of 
psychosis (UHR). 
Methods: We studied 345 UHR individuals of the high-risk study of the European network of national schizo-
phrenia networks studying Gene-Environment Interactions (EU-GEI). Smoking status and the number of ciga-
rettes per day were assessed at multiple moments using the CIDI. Symptom severity at each time point was 
assessed using CAARMS. Linear mixed-effects analyses were conducted to examine the multi-cross-sectional and 
prospective associations between (change in) smoking behaviour and symptomatology. 
Findings: At baseline, 175 individuals (53%) smoked tobacco with an average of 12.4 (SD = 9.0) cigarettes per 
day. Smokers did not significantly differ in symptom severity from non-smokers on general, positive, negative, 
emotional, cognitive, behavioural, or motor symptoms across time. However, associations were found between 
the number of cigarettes and the severity of general psychopathology (estimate 0.349, SE 0.146, p = 0.017). 
Change in the number of cigarettes had no significant effect on change in general symptom severity (estimate 
0.330, SE 0.285, p = 0.248). 
Interpretation: Smoking prevalence in UHR individuals is high. Cigarette consumption was associated with higher 
levels of general symptoms. However, we observed no association between change in number of cigarettes and 
symptom severity. Given the fact that smoking is associated with poorer health and worse outcomes in people 
with psychosis, the clinical high-risk phase offers a window of opportunity for prevention and cessation 
interventions.   
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1. Introduction 
Tobacco use is the leading cause of preventable diseases, disabilities, 
and death in Western countries. According to the World Health Orga-
nization (World Health Organization, 2017; Kotov et al., Jan 2010) to-
bacco use is responsible for killing more than seven million people each 
year globally, and one in ten deaths around the world is caused by to-
bacco use. In the past decades, the prevalence of smoking has been 
decreased in daily life in Western countries: the overall global rate of 
current smoking aged over 15 years, declined from 23.5% in 2007 to 
20.7% in 2015 (Organization WH, 2017). However, this is not the case 
for individuals with a psychiatric condition, and especially not in psy-
chosis: the smoking prevalence remains extremely high, with rates 
varying from 57.0% in first-episode psychosis (Gurillo et al., 2015) and 
61.6% in schizophrenia (Zeng et al., Jun 6 2020). Smoking has been 
associated with higher levels of symptom severity, especially positive 
(Vermeulen et al., 2019; Oluwoye et al., Feb 2019; Huang et al., 2019), 
negative (Oluwoye et al., Feb 2019) and depressive symptoms (Kotov 
et al., Jan 2010) in subjects with a psychotic disorder. 
To further understand the association between smoking and psy-
chotic symptoms, it is essential to evaluate this link in different stages of 
the illness. Individuals who are susceptible to develop a psychosis, but 
did not yet cross the threshold for a psychotic disorder are of great in-
terest, since the onset of smoking often predates the onset of psychosis. A 
recent literature review (Gogos et al., 2019) evaluated nicotine con-
sumption during the clinical high risk phase of psychosis. The smoking 
prevalence in individuals at risk for psychosis, also referred to as ultra- 
high risk (UHR), was higher compared to healthy controls, with rates 
between 16.6 and 46% in UHR. In addition, UHR subjects were almost 
five times as likely to be heavy smokers compared to unaffected subjects 
(Ward et al., Oct 2019). Limited evidence was found to suggest that 
tobacco use in UHR was associated with an increased risk to transition to 
psychosis (Gogos et al., 2019; Ward et al., Oct 2019). The authors (Gogos 
et al., 2019) attempted to evaluate whether UHR subjects who smoked 
differed from non-smoking UHR subjects regarding cognition and clin-
ical symptoms. Two studies examined cognitive performance (Gupta 
and Mittal, 2014; Cadenhead, 2011) in UHR individuals and concluded 
that smoking UHR individuals outperformed their non-smoking peers. 
With respect to the associations with clinical symptoms, the authors 
concluded that data were insufficient and the need for prospective 
studies was highlighted. 
This present study aimed to address this issue in a prospective study 
of a large sample of UHR subjects. We first tested the hypothesis that 
tobacco use would be multi-cross-sectionally associated with higher 
severity of symptoms (general, positive, negative, emotional, cognitive, 
behavioural, and motor change symptoms). Based on previous studies, 
we expected that the severity of symptoms would be positively associ-
ated with the number of cigarettes smoked per day (Vermeulen et al., 
2019). Second, we investigated the relationship between change in 
smoking behaviour and change in symptoms over time. Due to previous 
conflicting results in individuals with a psychiatric condition (Taylor 
et al., Feb 13 2014) and individuals with psychosis (Kotov et al., Jan 
2010; Vermeulen et al., 2019), we expected that change in smoking 
behaviour would not be associated with diminished nor increased 
symptom severity. 
2. Methods 
2.1. Study design 
Participants were part of the high-risk study of the European network 
of national schizophrenia networks studying gene-environment In-
teractions (EU-GEI) cohort (Schizophrenia ENoNNsG-EIi et al., Jul 2014; 
Menghini-Muller et al., Jun 2019). The overall aim of EU-GEI is the 
identification of clinical, genetic, and environmental interactions in the 
development, severity, and course of psychotic disorders in participants 
and their families. EU-GEI is a multicentre, naturalistic prospective 
study conducted between May 1, 2010, to April 30, 2015, and consisted 
of a baseline measurement and three follow-up time points (at six 
months, one year, and two years). 
2.2. Participants 
In our study, 345 UHR individuals were included. Participants were 
aged between 15 and 45 years and were recruited from 11 early 
detection centres (Amsterdam, Den Haag, Vienna, Basel, Cologne, 
Melbourne, Copenhagen, Paris, Barcelona, Sao Paulo, and London). 
Participants were included in the study if they met at least one of three 
UHR criteria as defined by the Comprehensive Assessment of At-risk Mental 
State (CAARMS) (Yung et al., 2005): 1. The Vulnerability Group: a first- 
degree relative with a psychotic disorder or diagnosed with schizotypal 
personality disorder in combination with a significant drop in func-
tioning during at least 1 month in the previous year, 2. The Attenuated 
Psychotic Symptoms (APS) Group: the presence of subthreshold positive 
psychotic symptoms for at least 1 month during the past year, or 3. The 
Brief Limited Intermittent Psychotic Symptoms (BLIPS) Group: an 
episode of frank psychotic symptoms that lasted no longer than 1 week, 
which abated spontaneously. Exclusion criteria were: prior experience 
of a psychotic episode of more than one week, as determined by the 
CAARMS (Yung et al., 2005), or an intelligence quotient (IQ) below 60. 
For the current study, UHR subjects were included if they provided data 
on smoking at baseline and psychopathology (CAARMS) at least at one 
assessment. All participants provided informed, written consent 
following a full explanation of the study. Relevant research ethics 
committees in each of the study sites provided ethical approval. 
2.3. Assessment instruments 
Detailed information about the use of tobacco during the past year 
was assessed using the Composite International Diagnostic Interview (CIDI) 
which has been found to be reliable in a cross-cultural trial (Cottler et al., 
1989). Smokers were defined as people who smoked daily for at least 
one month over the past 12 months. Data on the use of cigars, chewing 
and snuffing tobacco or on the use of electronic nicotine delivery sys-
tems were not available in the current study. Participants were asked 
how many cigarettes they smoked per day in the time frame they 
smoked the most during the past 12 months. Symptom severity was 
assessed using the CAARMS (Yung et al., 2005), a semi-structured 
interview designed to assess the at-risk mental states for psychosis. 
The CAARMS provides ordinal scores for the severity of psychotic 
symptoms as well as other dimensions of psychopathology (Morrison 
et al., 2012). In our study, outcome variables were based on the seven 
symptom domains of the CAARMS, namely: positive symptoms (items: 
unusual thought content, non-bizarre ideas, perceptual abnormalities, 
disorganized speech); negative symptoms (alogia, avolition/apathy, 
anhedonia); motor/physical change (subjective complaints of impaired 
motor functioning, observed change in motor functioning); behavioural 
change (social isolation, impaired role function, disorganizing/odd/ 
stigmatizing behaviour, aggression/dangerous behaviour); cognitive 
change attention/concentration (subjective experience, observed 
cognitive change); emotional disturbance (subjective emotional distur-
bance, observed blunted affect, observed inappropriate affect) and 
general psychopathology (mania, depression, suicidality/self-harm, 
mood swings/lability, anxiety, obsessive-compulsive symptoms, disso-
ciative symptoms and subjective impaired tolerance to normal stress). 
The composite score for our outcome variables (7 subscales) was 
computed by summing intensity * frequency score (both scored on a 
Likert scale 0 to 6) of the corresponding items, as per previous research 
(Morrison et al., 2012; Lim et al., 2015). See supplement 1 and 2 for 
detailed information about available data for smoking status and 
CAARMS subscales. 
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2.4. Covariates 
All participants provided information on sociodemographic features, 
such as their gender, age, education, and current employment. Social 
functioning was scored using the Global Assessment of Functioning (GAF, 
range 0–100) (Goldman et al., 1992). The Cannabis Experience Ques-
tionnaire (CEQ) was administered to assess information regarding the 
use of cannabis. Participants answered either “yes” or “no” in response 
to being asked, “Do you currently use marijuana?” Those who reported 
“yes” to cannabis use were classified as “cannabis users.” The Childhood 
Trauma Questionnaire (CTQ) serves as a valid retrospective assessment of 
childhood trauma (Liebschutz et al., Jun 2018). This 25-item self-report 
questionnaire assesses traumatic events before the age of 17 and was 
used to report information on 5 subscales (emotional abuse, physical 
abuse, sexual abuse, emotional neglect, and physical neglect), as well as 
a total score of all 5 subscales (range 0-6). Age, gender, socioeconomic 
status (including education, current employment, and GAF scores), 
childhood trauma, and cannabis use were a-priori selected as covariates 
since these variables were found to be associated with both smoking and 
symptom severity (Kotov et al., Jan 2010; Vermeulen et al., 2019; Kraan 
et al., 2018). 
2.5. Statistical analyses 
Statistical analyses were performed in IBM SPSS Statistics version 26 
(Chicago, Illinois, USA). Complete case analysis at baseline revealed 
missing data on several items (supplement 4) that were missing at 
random. Therefore, multiple imputation was applied which is a gener-
ally accepted solution to deal with incomplete data (van Buuren et al., 
1999; Sterne et al., Jun 29 2009; van Buuren, 2012). Multiple imputa-
tion was applied at baseline for socioeconomic status (including edu-
cation, current employment, and GAF scores), CAARMS individual 
items, and information about the use of cannabis (current and lifetime 
use). Linear mixed models were used to assess associations between 
smoking and symptoms severity across different assessment times over a 
period of two years (multi-cross-sectional). This method allowed us to 
deal with the non-independence of the data due to repeated assessment. 
Every subject with at least one assessment was included and models 
were fitted using maximum likelihood estimation (Harrison et al., 2018; 
Seltman, 2012). We compared smoking and non-smoking participants 
on baseline characteristics with independent t-tests, Whitney U tests, 
and X2 for normal distributed, non-normal distributed and categorical 
data, respectively. Visual inspection of residual plots of all seven 
CAARMS subscales revealed no deviations from normality. Continuous 
variables were centered (Bolger and Laurenceau, 2013) to improve 
model performance and interpretability (Harrison et al., 2018). 
To answer the first research question, we set symptom severity as 
measured with seven subscales of the CAARMS as the outcome variables. 
In the first model, smoking status (yes/no), time, age, and gender were 
entered as fixed effects. If models showed significant results, the 
following a priori selected covariates were added en bloc: GAF, educa-
tion, work, cannabis, and trauma scores. In all models, subjects were 
added as random intercept and time was added as random slope. To 
investigate a dose-response relationship, we ran a second set of linear 
mixed effect models replacing smoking status by the number of 
cigarettes. 
To answer the second research question, three groups were identified 
between assessments (1 year compared to baseline, 2 years compared to 
1 year): participants who did not change their smoking behaviour, 
participants who were able to quit smoking, and participants who 
started smoking cigarettes. In addition, change scores regarding the 
number of cigarettes smoked were calculated. Furthermore, change 
scores on outcome variables were calculated. We applied two sets of 
linear mixed models with similar covariates as fixed, and random effects 
as mentioned earlier. P-values were calculated by the Satterthwaite 
method which has been evaluated in REML-fitted models and produced 
the most acceptable type I error rates in mixed-effects models (Luke, Aug 
2017). 
3. Results 
3.1. Sample characteristics 
345 UHR individuals participated in the EU-GEI study. Sociodemo-
graphic features and clinical characteristics are presented in Table 1. For 
the current analyses, only UHR individuals with data on smoking and at 
least one assessment with the CAARMS were included (n = 330). As we 
were interested in associations over an approximately two year period, 
assessments dates with extreme deviation (>1000 days from baseline) 
were excluded (n = 23) in the mixed model analysis. Assessments at six 
months were scarce in most inclusion sites, as this time point was 
introduced later in the study, and not due to any patient-specific reasons. 
Both CAARMS data (positive symptoms) and smoking status data were 
available for 41 (12.5%) individuals at six months, compared to 169 
(51.5%) and 123 (39.4%) at one- and two-year follow-up, respectively. 
See supplement 3 for other subscales. 
3.2. Baseline comparisons 
In total, 175 individuals (53%) smoked at baseline with an average of 
12.4 (SD = 9.0) cigarettes per day. Baseline comparisons showed that 
smokers were significantly older than non-smokers and reported more 
current or lifetime cannabis use. They also had lower GAF scores and 
had experienced significantly more physical abuse during childhood. 
Between-group comparisons (smokers vs. non-smokers) showed no sig-
nificant differences at baseline on any of the CAARMS subscales. In our 
sample, detailed information about medication use (i.e. dose- 
equivalents and compliance) was incomplete. Overall, 35% of smoking 
individuals used psychotropic medication, compared to 40% of non- 
smoking individuals. There were no significant between-group differ-
ences in transition rate between smoking UHR individuals and non- 
smoking individuals (see Table 1). 
3.3. Association between smoking and symptom severity 
Mixed model analyses showed no significant multi-cross-sectional 
differences between UHR individuals who did and did not smoke on 
any outcome variable (supplement 5). 
3.4. Association between the number of cigarettes smoked per day and 
symptom severity 
A positive association was found between the number of cigarettes 
and the severity of general psychopathology (estimate 0.376, SE 0.146, 
p = 0.010). This association remained after correcting for confounding 
variables (estimate 0.349, SE 0.146, p = 0.017), as shown in Table 2. 
Besides general symptoms, a positive association was also found 
between the number of cigarettes smoked per day and behavioural 
change symptoms (estimate 0.219, SE 0.099, p = 0.026). However, 
significance was lost after correction for confounding variables (sup-
plement 6). We found no significant association between the number of 
cigarettes smoked per day and symptom severity on the other five 
CAARMS subscales (positive, negative, emotional, cognitive, or motor 
change symptoms) (supplement 6). 
3.5. Association between change in number of cigarettes smoked and 
change in symptom severity 
Post hoc exploratory analyses did not show a significant association 
between change in the number of cigarettes smoked and change in the 
severity of general psychopathology (estimate 0.330, SE 0.285, p =
0.248) (supplement 7). 
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4. Discussion 
This prospective, longitudinal study showed that smoking preva-
lence among people at UHR for psychosis was high (53%). No associa-
tions were found between smoking status and symptom severity in UHR 
individuals, nor between smoking status and transition rate. However, 
we observed a dose-response relationship between the number of 
cigarettes smoked per day and higher levels of general symptom severity 
in UHR individuals. A smoking prevalence of 53% in the current UHR 
sample is substantially higher compared with the general population, 
but somewhat lower compared to subjects with psychosis (Chapman 
et al., Mar 2009; Parikh et al., 2016; Volkow, 2009). A systematic review 
focussing on cardiometabolic risk factors in UHR individuals (Carney 
et al., 2016) found an overall smoking prevalence of 33%. However, 
many of the studies in this systematic review excluded individuals with 
comorbid substance abuse. This might suggest that the overall smoking 
prevalence in the latter study was underestimated because tobacco 
smoking and comorbid substance abuse frequently co-occur. Our results 
are in line with two other smaller studies (Gupta and Mittal, 2014; 
Egerton et al., 2014) (N = 35 and N = 75), which found a smoking 
prevalence of 46 and 61%, respectively. 
In contrast with our first hypothesis, we found no significant asso-
ciation between smoking status (yes or no) and symptom severity in 
UHR individuals. To the best of our knowledge, we could not find pre-
vious studies that examined the association between smoking and 
symptom severity in UHR. Our findings are at odds with the evidence in 
individuals who already crossed the diagnostic border of a psychotic 
disorder, in whom a positive association between smoking status and 
higher symptom levels of positive, negative, and depressive symptoms 
was reported (Vermeulen et al., 2019; Oluwoye et al., 2019). Current 
findings could be viewed as partially in line with results from a recent 
meta-analysis (Huang et al., 2019) which found more positive symptoms 
in smoking subjects with psychosis, but no effect on negative, depres-
sive, and anxiety symptoms. 
Several, non-mutually exclusive hypotheses exist trying to explain 
the relationship between tobacco smoking and symptom severity in in-
dividuals with psychiatric illnesses, such as causal relationship (Kendler 
et al., 2015; Mustonen et al., 2018; Wootton et al., 2019), a shared 
vulnerability (Gage and Munafo, 2015; Hu et al., 2018; Liu et al., 2019), 
dysfunctional coping (Moon et al., 2014), or self-medication (Kumari 
and Postma, 2005; Dome et al., 2010). In our study, the smoking prev-
alence of UHR individuals is 3-fold higher than in healthy controls 
(Fusar-Poli et al., 2017). Multiple studies (Gurillo et al., 2015; Kendler 
et al., 2015; Mustonen et al., 2018; Wootton et al., 2019) found that 
smoking is a causal risk factor for developing psychosis. It is hypothe-
sized that nicotine disrupts neurotransmitters and that toxic compounds 
in cigarettes may induce immune upregulation, which might contribute 
to the onset of mental illness. With regard to this hypothesis, no con-
clusions can be drawn as the current study was not designed to study 
whether smoking has a causal effect on psychosis. 
We found no association between smoking and transition, which is in 
line with results from Ward et al., who evaluated the role of nicotine in 
the development of psychosis (Ward et al., 2019). The high prevalence 
of smoking in the early at-risk mental state may support the hypothesis 
that shared genetic and environmental risk factors account for the co- 
existence of smoking and (subclinical) psychotic symptoms. Liu et al. 
(Liu et al., 2019) found evidence for a genetic correlation between 
schizophrenia and smoking, with overlapping genome-wide associated 
single nucleotide polymorphisms in the gene cluster coding for nicotine 
Table 1 




N = 155 (47%) 
Value p- 
Value* 
Gender     
Male 100 (57%) 77 (50%) X =
1842 
0,186 
Female 75 (43%) 78 (50%)   
Age 23,1 (5,0) 21,7 (4,8) Z =
− 2813 
0,005†
GAF 53,8 (11,3) 57,6 (13,4) T =
2818 
0,005 
Education in years 14,19 (3,1) 14,38 (3,1) T =
0,556 
0,579 
Current employment     
No paid work 82 (47%) 60 (39%) X =
2226 
0,136 
Student/paid work 93 (53%) 95 (61%)   
Cannabis     





68 (39%) 17 (11%) X =
33.433 
<0,001 
Trauma     
Emotional abuse 2,5 (1,0) 2,4 (1,1) Z =
− 0,891 
0,373†
Physical abuse 1,6 (0,8) 1,4 (0,7) Z =
− 2214 
0,027†
Sexual abuse 1,5 (0,9) 1,4 (0,8) Z =
− 1833 
0,067†
Emotional neglect 2,7 (1,0) 2,7 (1,0) Z =
− 0,900 
0,368†
Physical neglect 1,7 (0,7) 1,7 (0,6) Z =
− 0,355 
0,722†
Total trauma score 9,5 (3,1) 9,9 (3,2) Z =
1393 
0,164 
CAARMS     
General 
psychopathology 
58,9 (29,2) 54,7 (28,9) Z =
− 1077 
0,281†
Positive symptoms 37,3 (19,5) 36,8 (19,9) T =
− 0,228 
0,820 




















7,5 (10,1) 6,9 (9,0) Z =
− 0,188 
0,851†
Medication     
Current use of 
antipsychotics 




Current use of 
antidepressants 




Current use of 
anxiolytics 






175 155   




No 145 (83%) 123 (79%)   
Data are in N (%) or mean (SD). GAF: Global Assessment of Functioning. 
CAARMS: Comprehensive Assessment of At-risk Mental State. Imputated data: 
GAF scores, education, current employment, cannabis, trauma scores and indi-
vidual CAARMS items. Two sides p-values were computed by an independent t- 
test, Mann-Whitney U test† or a X2 test. 
Table 2 
Results of liner mixed model regarding the multi-cross sectional association 
between amount of cigarettes and general psychopathology in UHR individuals.  
CAARMS: general psychopathology  
Estimate SE p 
Intercept 28,960 6234 <0,001 
Amount of cigarettes 0,349 0,146 0,017 
Time -6924 0,825 0,000 
CAARMS: Comprehensive Assessment of At-risk Mental State. The following 
fixed effects were added to the model: age + gender + time, GAF scores, edu-
cation, work, cannabis and trauma scores. Subject was added as random inter-
cept and time was added as random slope. 
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receptor subunits. Second, smoking and schizophrenia share important 
environmental risk factors such as socioeconomic status, traumatic 
events and drug abuse (Kendler et al., 2015; Fusar-Poli et al., 2020; Do 
and Maes, 2017) that may account for a part of the explained variance in 
the link between smoking and psychosis. Therefore, individuals with a 
high risk for psychosis might also be genetically and environmentally 
more prone to start smoking compared to the general population. This 
explanation is also plausible for the association between depressive 
symptoms or disorder and smoking. One study (Edwards et al., 2011) 
evaluating same-sex twins from the general population found that both 
genetic and environmental influences contribute to the co-occurrence of 
depression and smoking in females. 
Although we found no associations with smoking status, we found an 
association between the number of cigarettes smoked per day and the 
severity of general symptoms. As mentioned above, the majority of items 
included in the general symptoms subscale measures affective symp-
toms. Depressive and anxiety disorders are the main reasons why UHR 
individuals seek help as they cause substantial distress (Falkenberg 
et al., 2015). In addition to possible shared underlying vulnerabilities, 
the high prevalence of smoking and associations with more affective 
symptoms might support an alternative hypothesis of dysfunctional 
coping. Higher levels of depression and anxiety in UHR individuals have 
been found associated with maladaptive coping patterns (Lee et al., 
2011). According to a systematic review (Mian et al., 2018), UHR in-
dividuals use indeed more maladaptive coping, negative, avoidant and 
fewer adaptive coping strategies than healthy controls. In this line, 
smoking may represent a maladaptive coping strategy (Clark et al., 
2017), in trying to cope with the presence of anxiety and or depressive 
symptoms instead of applying other (more healthy) behavioural strate-
gies to alleviate these symptoms. One study in UHR found indeed that 
stressful life events were associated with an increased risk to smoke 
(Ward et al., Oct 2019). However, maladaptive avoidant coping strate-
gies (including smoking) may also lead to increased general symptom 
severity (Lee et al., Feb 2011). 
With respect to the self-medication hypothesis (Kumari and Postma, 
2005; Dome et al., 2010), stimulation of nicotinic-acetylcholine re-
ceptors triggers a release of a variety of neurotransmitters which might 
alleviate psychiatric symptoms. In our study, the association with more 
severe general symptoms and the lack of an association between change 
in the number of cigarettes and symptom severity challenges the self- 
medication hypothesis. This is in line with several recent studies in 
psychosis. For example, a multicentre, longitudinal cohort study (Ver-
meulen et al., 2019) found that smoking cessation was not associated 
with changes in symptoms while starting smoking was associated with 
an increase in positive symptoms. Interestingly, smoking might also be 
relevant for other symptom domains such as cognitive functioning. Two 
studies (Gupta and Mittal, 2014; Cadenhead, 2011) in UHR individuals 
found that nicotine use was associated with improved functioning on 
certain cognitive domains and the authors hypothesized that influence 
on nicotinic-acetylcholine receptors could lead to enhanced cognitive 
function, at least over the short term (also known as the gating deficit 
hypothesis (Brockhaus-Dumke et al., 2008; Turetsky et al., 2012)). 
4.1. Strengths and limitations 
The main strengths of the current study are the prospective, longi-
tudinal design and the inclusion of a large sample of UHR participants. 
Furthermore, this study was conducted in a wide range of settings across 
the world. This maximises its generalisability and importance for public 
health interventions. However, the current study has several limitations 
that should be acknowledged. First, due to the observational design of 
our study, reverse causation and residual confounding cannot be ruled 
out. A second limitation is the lack of information regarding the initia-
tion of tobacco use prior to symptoms. A meta-analysis (Myles et al., 
2012) found that tobacco use begins on average five years before the 
onset of psychosis. A third limitation of this study is the lack of a control 
group. Fourth, assessments at six months were scarce (12.5%) in most 
centres due to differences in study design procedures. Nevertheless, in 
evaluating change scores over time we compared symptomatology and 
the number of cigarettes based on a one-year scale (2 years compared to 
1 year, 1 year compared to baseline). However, also a substantial 
number of participants was lost to follow-up (49% and 61%) at one and 
two years, respectively. As a consequence, the limited sample size may 
have underpowered the change analysis. Fifth, we were not able to 
present an analysis using medication doses because detailed data was 
incomplete. Therefore, the use of medication was not included as a 
confounding variable. However, sensitivity analyses were done in a sub- 
sample of UHR (N = 272) individuals which revealed the same results as 
the primary analyses. Finally, the fact that only individuals who were 
seeking help were included indicates that a selection bias could be 
present and that these findings should be generalised with caution. 
4.2. Clinical implications 
Our findings concerning a high prevalence of smoking, an associa-
tion between smoking severity and severity of general symptoms and the 
lack of any beneficial effects support the goal of prevention and stopping 
smoking in subjects at UHR. A recent meta-analysis and randomised 
controlled trial (Gilbody et al., 2019) showed that subjects with severe 
mental illness are a harder-to-treat population (Zeng et al., 2020). This 
means that they need more quit attempts and more support. Since UHR 
individuals suffer less from symptoms than individuals with a first 
psychotic episode, this phase might be a window of opportunity to 
provide smoking cessation support. Early intervention smoking cessa-
tion programs should therefore be offered when UHR individuals pre-
sent to psychiatric services. The knowledge that number of cigarettes 
smoked was associated with more severe general symptomatology and 
that anxiety, depression, and stress can decrease after smoking cessation 
(Taylor et al., 2014), will hopefully boost motivation to decrease or stop 
smoking. 
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